Larimar Therapeutics (LRMR) EV to FCF (2020 - 2025)
Larimar Therapeutics' (LRMR) quarterly EV to FCF came in at 4392.26 in Q3 2025, down 50353.5% on a YoY basis from N/an in Q3 2024, and down 183081.5% quarter-over-quarter from 2.4 in Q2 2025.
Powered by 
Analysis
Larimar Therapeutics (LRMR) EV to FCF (2020 - 2025) Analysis & Trends
Larimar Therapeutics (LRMR) has reported EV to FCF for 6 consecutive years, with 4392.26 the latest figure, recorded in Q3 2025.
- For the quarter ending Q3 2025, EV to FCF fell 50353.5% year-over-year to 4392.26; the trailing twelve-month figure through Dec 2025 stood at 3.91 (down 338.6% YoY), and the FY2025 full-year result was 1.59, down 78.13% from the prior year.
- EV to FCF eased to 4392.26 in Q3 2025 per LRMR's latest filing, from 2.4 in the prior quarter.
- Across five years, EV to FCF topped out at 9.11 in Q3 2022 and bottomed at 4392.26 in Q3 2025.
- Historically, EV to FCF has averaged 237.63 across 5 years, with a median of 8.47 in 2023.
- The sharpest annual moves came in 2022 and 2025: EV to FCF jumped 193.1% in 2022, then sank 50353.5% in 2025.
- Over 5 years, EV to FCF stood at 15.26 in 2021, then jumped by 111.82% to 1.8 in 2022, then plunged by 755.9% to 11.83 in 2023, then surged by 75.63% to 2.88 in 2024, then sank by 152283.24% to 4392.26 in 2025.
- According to Business Quant data, EV to FCF over the past three periods registered 4392.26, 2.4, and 0.75 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | Larimar Therapeutics | 397.87 Mn | 241.60 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | -4,392.26 |
| Jun 30, 2025 | -2.40 |
| Mar 31, 2025 | 0.75 |
| Dec 31, 2024 | -2.88 |
| Sep 30, 2024 | -8.71 |
| Jun 30, 2024 | -16.60 |
| Mar 31, 2024 | -24.64 |
| Dec 31, 2023 | -11.83 |
| Sep 30, 2023 | -8.47 |
| Jun 30, 2023 | -4.23 |
| Mar 31, 2023 | -11.20 |
| Dec 31, 2022 | 1.80 |
| Sep 30, 2022 | 9.11 |
| Jun 30, 2022 | 2.70 |
| Mar 31, 2022 | -1.20 |
| Dec 31, 2021 | -15.26 |
| Sep 30, 2021 | -9.79 |
| Jun 30, 2021 | -7.47 |
| Mar 31, 2021 | -12.40 |
| Dec 31, 2020 | -15.78 |